Global AI in Medical Imaging Horizon: Forecasts, Competitive Architecture, and Reimbursement-Driven Monetization, 2024A-2035E

This Marketstrat® Horizon report provides a global 2024A–2035E analysis of artificial intelligence in medical imaging, including market sizing, segment forecasts, reimbursement-driven monetization, competitive architecture, regulatory and evidence trends, and strategic implications for vendors, providers, and investors.

The Global AI in Medical Imaging Horizon: Forecasts, Competitive Architecture, and Reimbursement-Driven Monetization, 2024A–2035E is a comprehensive Marketstrat® / Markintel® Horizon report analyzing the global market for AI-attributable revenue across medical imaging. The report evaluates how artificial intelligence is being commercialized across CT, MRI, X-ray / digital radiography, mammography / DBT, ultrasound, nuclear imaging, and PET, and how AI value is shifting from stand-alone algorithms toward workflow integration, reimbursement maturity, enterprise deployment, cloud / pay-per-use economics, and recurring software models.

The report is built around a reconciled 2024A–2035E market model and covers the major commercial dimensions of medical imaging AI: modality, clinical area, clinical application, technology layer, revenue stream, end-user organization, geography, and reimbursement tier. The base-case forecast places the global AI medical imaging market at approximately $3.8B in 2024A and approximately $33.6B by 2035E, with growth shaped by reimbursement expansion, enterprise platform adoption, AI-enabled productivity, cloud deployment, and disease-specific quantitative analytics.

Unlike reports that focus primarily on regulatory clearance counts or vendor lists, this report emphasizes monetization. It explains why AI tools with similar technical or regulatory profiles may monetize differently depending on payer coverage, workflow integration, clinical evidence, procurement model, buyer type, and enterprise deployment path. It also introduces a reimbursement-tier framework that separates mature reimbursed AI, developing reimbursement categories, non-reimbursed productivity AI, and hardware-embedded / out-of-tier AI.

The report includes detailed analysis of competitive positioning across imaging OEMs, enterprise imaging / PACS platforms, AI-native clinical platforms, reimbursed quantitative analytics specialists, breast and oncology AI vendors, reconstruction and acquisition AI vendors, generative reporting and workflow automation companies, orchestration and governance platforms, cloud infrastructure providers, and provider-network AI platforms.

Key areas covered

Global AI medical imaging market forecast, 2024A–2035E
TAM / SAM / expected market framing
Market sizing by region, modality, clinical area, clinical application, revenue stream, technology layer, end-user organization, and reimbursement tier
Base, bull, bear, and sensitivity scenarios
Reimbursement-driven monetization and payment policy implications
FDA, De Novo, Breakthrough Device, PCCP, EU AI Act / MDR, NMPA, PMDA / NHI, and other regulatory considerations
Cardiac CT AI reimbursement and quantitative analytics
Mammography and screening AI evidence pathways
Enterprise imaging, PACS, reporting, orchestration, and AI governance
Foundation-model and multi-condition AI strategy
Cloud / pay-per-use and enterprise software monetization
Provider-owned AI networks, teleradiology, and outpatient imaging economics
Competitive landscape and M&A / partnership implications
Strategic execution playbooks by stakeholder type

Market segmentation

By modality: CT AI; MRI AI; X-ray / DR / mammography AI; ultrasound AI; nuclear / PET AI.
By clinical area: oncology, cardiology, neurology, respiratory / pulmonary, orthopedics / MSK, multispecialty AI.
By application: detection and diagnosis; workflow and orchestration; image reconstruction and acquisition; quantification and analytics; reporting and communication.
By revenue stream: hardware-embedded AI; installed / enterprise software; professional / managed services; cloud / pay-per-use.
By technology layer: deep learning, computer vision, traditional ML / radiomics, NLP / generative AI, robotics / automation, expert systems, foundation-model / multimodal AI.
By end user: hospitals / IDNs, imaging centers / radiology groups, teleradiology providers, clinics / specialist offices, government / mobile / military / NGO.
By geography: North America, Europe, APAC, Latin America, Middle East and Africa, with major country coverage.

Competitive landscape

The report analyzes the competitive landscape across the major AI imaging control points, including imaging OEMs, enterprise imaging vendors, PACS / RIS / VNA platforms, AI-native clinical platforms, reimbursed quantitative analytics companies, breast and oncology AI vendors, reconstruction and acquisition AI companies, reporting and workflow automation vendors, AI orchestration / governance platforms, cloud infrastructure providers, and provider-network AI platforms.

Companies discussed include GE HealthCare, Siemens Healthineers, Philips, Canon Medical, Fujifilm, United Imaging, Pro Medicus, Sectra, Intelerad, AGFA HealthCare, Aidoc, Viz.ai, RapidAI, Qure.ai, Annalise.ai, DeepHealth / RadNet, HeartFlow, Cleerly, Elucid, Circle Cardiovascular Imaging, Lunit, iCAD, ScreenPoint, Hologic, Vara, Rad AI, Microsoft / Nuance, deepc, CARPL.ai, Ferrum Health, Blackford, Incepto, AWS, Microsoft Azure, Google Cloud, NVIDIA, and others.

Why purchase this report

This report helps users:

evaluate the size and structure of the global medical imaging AI market
identify which AI imaging categories have the strongest monetization potential
understand how reimbursement affects adoption, pricing, and defensibility
compare opportunity across modalities, clinical areas, and technology layers
benchmark competitive positioning across OEMs, PACS vendors, AI platforms, provider networks, and cloud infrastructure providers
assess M&A, partnership, and market-entry opportunities
support strategy, corporate development, investment, product planning, and GTM decisions

Report details

Publisher: Marketstrat®
Series: Markintel® Horizon Report
Publication: June 2026
Report ID: MINTH-D01101-26A
Forecast period: 2024A–2035E
Length: 300+ pages
Tables / figures: 140+ tables and 70+ figures / frameworks
Geographic coverage: Global, North America, Europe, APAC, LATAM, MEA, and major country markets

Product Code: MINTH-D01101-26A

SECTION 1 - EXECUTIVE SUMMARY

1.1 EXECUTIVE TAKEAWAYS
1.2 GLOBAL MARKET AT-A-GLANCE - BASE CASE
1.3 WHAT IS STRUCTURALLY CHANGING
1.4 THE AI MONETIZATION LAYER: WHERE VALUE IS MOVING
1.5 COMPETITIVE SIGNAL DASHBOARD
1.6 STRATEGIC IMPLICATIONS BY STAKEHOLDER
1.7 MARKETSTRAT VIEW: WINNERS AND VULNERABLE SEGMENTS
1.8 SIGNALS TO WATCH OVER THE NEXT 12–24 MONTHS
1.9 EXECUTIVE CONCLUSION

SECTION 2 - RESEARCH & METHODOLOGY

2.1 WHAT THIS REPORT IS - AND WHAT IT IS NOT
2.2 RESEARCH FOUNDATION AND EVIDENCE BASE
2.3 METHODOLOGY ARCHITECTURE
2.4 MARKET DEFINITION
2.5 SEGMENTATION SCHEMA
2.6 GEOGRAPHIC METHODOLOGY
2.7 CORE MARKET SIZING AND FORECASTING METHODOLOGY
2.8 REVENUE STREAM AND AI MONETIZATION METHODOLOGY
2.9 REIMBURSEMENT TIER METHODOLOGY
2.10 MARKET STRUCTURE VIEWS
2.11 COMPETITIVE LANDSCAPE METHODOLOGY
2.12 STRATEGIC FRAMEWORK METHODOLOGY
2.13 QUALITY CONTROL, RECONCILIATION, AND REPRODUCIBILITY
2.14 LIMITATIONS AND GUIDANCE FOR INTERPRETATION

SECTION 3 - STRATEGIC FRAMEWORKS & MARKET STRUCTURE

3.1 EXECUTIVE TAKEAWAYS
3.2 WORLD MARKET OVERVIEW
3.3 MARKET STRUCTURE - WHAT IS STRUCTURALLY CHANGING
3.4 MARKET STRUCTURE VIEWS
3.5 STRATEGIC FRAMEWORKS ARCHITECTURE
3.6 M³ MARKET MOMENTUM VIEW
3.7 TECHNOLOGY MATURITY VIEW
3.8 AI REVENUE BY STREAM - BRIDGE VIEW
3.9 REIMBURSEMENT TIER MARKET STRUCTURE
3.10 T-DIC - TECHNOLOGY DIFFUSION & IMPACT CURVE
3.11 SOLUTION ADOPTION & GROWTH
3.12 AI USE-CASE MONETIZATION ARCHITECTURE
3.13 GTM GROWTH–MATURITY MATRIX
3.14 ECOSYSTEM COLLABORATION
3.15 CONTROL PLANE MAP
3.16 PARTNERING DECISION TREE
3.17 ARC COMMERCIAL READINESS
3.18 UPGRADE & PACKAGE LADDER
3.19 AI REVENUE BRIDGE - 2024A TO 2035E
3.20 STRATEGIC IMPLICATIONS BY STAKEHOLDER TYPE
3.21 SIGNALS TO WATCH
3.22 BOTTOM LINE

SECTION 4 - COMPETITIVE LANDSCAPE & COMPANY SPOTLIGHTS

4.1 EXECUTIVE TAKEAWAYS
4.2 COMPETITIVE LANDSCAPE MAP
4.3 CROSS-CUTTING COMPETITIVE THESIS
4.4 COMPETITIVE POSITIONING FRAMEWORK
4.5 CLUSTER 1 - IMAGING OEM PLATFORM INCUMBENTS
4.6 CLUSTER 2 - ENTERPRISE IMAGING, PACS, VIEWER, AND WORKFLOW PLATFORMS
4.7 CLUSTER 3 - AI-NATIVE CLINICAL PLATFORMS
4.8 CLUSTER 4 - REIMBURSED AND QUANTITATIVE SPECIALTY ANALYTICS
4.9 CLUSTER 5 - BREAST, ONCOLOGY, AND SCREENING AI
4.10 CLUSTER 6 - RECONSTRUCTION, ACQUISITION, AND SCANNER PRODUCTIVITY AI
4.11 CLUSTER 7 - GENERATIVE REPORTING, FOLLOW-UP, AND WORKFLOW AUTOMATION
4.12 CLUSTER 8 - ORCHESTRATION, MARKETPLACE, CLOUD, AND GOVERNANCE
4.13 CLUSTER 9 - PROVIDER-NETWORK AI PLATFORMS AND TELERADIOLOGY
4.14 CLUSTER 10 - CHINA AND APAC CHAMPIONS
4.15 COMPANY SPOTLIGHTS - STRATEGIC LEADERS
4.16 COMPETITIVE WINNERS AND PRESSURE POINTS
4.17 M&A AND PARTNERSHIP OUTLOOK
4.18 STRATEGIC IMPLICATIONS BY STAKEHOLDER
4.19 SIGNALS TO WATCH
4.20 COMPETITIVE SIGNALS TIMELINE
4.21 BOTTOM LINE

SECTION 5 - MARKET ANALYSIS BY REGION / COUNTRY

5.1 EXECUTIVE TAKEAWAYS
5.2 GLOBAL REGIONAL FORECAST OVERVIEW
5.3 REGIONAL COMMERCIAL ARCHETYPES
5.4 NORTH AMERICA
5.5 UNITED STATES
5.6 CANADA
5.7 EUROPE
5.8 GERMANY
5.9 FRANCE
5.10 UNITED KINGDOM
5.11 ITALY
5.12 REST OF EUROPE
5.13 APAC
5.14 CHINA
5.15 JAPAN
5.16 INDIA
5.17 REST OF APAC
5.18 LATAM
5.19 MEA
5.20 COUNTRY-LEVEL OPPORTUNITY SCORECARD
5.21 REGIONAL GTM PLAYBOOKS
5.22 REGIONAL SIGNALS TO WATCH
5.23 STRATEGIC IMPLICATIONS BY STAKEHOLDER
5.24 REGIONAL GTM MOTION

SECTION 6 - MARKET ANALYSIS BY IMAGING MODALITY

6.1 EXECUTIVE TAKEAWAYS
6.2 GLOBAL FORECAST BY IMAGING MODALITY
6.3 MODALITY COMMERCIAL ARCHETYPES
6.4 CT AI
6.5 MRI AI
6.6 X-RAY / DR / MAMMOGRAPHY AI
6.7 ULTRASOUND AI
6.8 NUCLEAR / PET AI
6.9 CROSS-MODALITY COMPETITIVE DYNAMICS
6.10 MODALITY PRIORITY MATRIX
6.11 MODALITY-SPECIFIC GTM PLAYBOOKS
6.12 SIGNALS TO WATCH BY MODALITY
6.13 STRATEGIC IMPLICATIONS BY STAKEHOLDER
6.14 BOTTOM LINE

SECTION 7 - MARKET ANALYSIS BY CLINICAL AREA

7.1 EXECUTIVE TAKEAWAYS
7.2 GLOBAL FORECAST BY CLINICAL AREA
7.3 CLINICAL-AREA COMMERCIAL ARCHETYPES
7.4 ONCOLOGY IMAGING AI
7.5 CARDIOLOGY IMAGING AI
7.6 NEUROLOGY IMAGING AI
7.7 RESPIRATORY / PULMONARY IMAGING AI
7.8 ORTHOPEDICS / MSK IMAGING AI
7.9 OTHER / MULTISPECIALTY IMAGING AI
7.10 CLINICAL AREA X MODALITY CROSSWALK
7.11 CLINICAL-AREA PRIORITY MATRIX
7.12 COMPETITIVE DYNAMICS BY CLINICAL AREA
7.13 SIGNALS TO WATCH BY CLINICAL AREA
7.14 STRATEGIC IMPLICATIONS BY STAKEHOLDER
7.15 BOTTOM LINE

SECTION 8 - MARKET ANALYSIS BY REVENUE STREAM AND MONETIZATION MODEL

8.1 EXECUTIVE TAKEAWAYS
8.2 GLOBAL FORECAST BY REVENUE STREAM
8.3 REVENUE STREAM DEFINITIONS
8.4 HARDWARE-EMBEDDED AI
8.5 INSTALLED / ENTERPRISE SOFTWARE
8.6 PROFESSIONAL / MANAGED SERVICES
8.7 CLOUD / PAY-PER-USE
8.8 PRICING AND PACKAGING ARCHETYPES
8.9 REVENUE STREAM BY REGION
8.10 REVENUE STREAM X CLINICAL AREA CROSSWALK
8.11 COMPETITIVE DYNAMICS BY REVENUE STREAM
8.12 SIGNALS TO WATCH, 2026–2030
8.13 STRATEGIC IMPLICATIONS BY STAKEHOLDER TYPE
8.14 BOTTOM LINE

SECTION 9 - MARKET ANALYSIS BY CLINICAL APPLICATION / USE CASE

9.1 EXECUTIVE TAKEAWAYS
9.2 GLOBAL FORECAST BY CLINICAL APPLICATION
9.3 CLINICAL APPLICATION DEFINITIONS
9.4 DETECTION & DIAGNOSIS
9.5 QUANTIFICATION & ANALYTICS
9.6 WORKFLOW & ORCHESTRATION
9.7 REPORTING & COMMUNICATION
9.8 IMAGE RECONSTRUCTION & ACQUISITION
9.9 CLINICAL APPLICATION X MODALITY CROSSWALK
9.10 CLINICAL APPLICATION X CLINICAL AREA CROSSWALK
9.11 REGIONAL MONETIZATION LOGIC BY APPLICATION
9.12 COMPETITIVE DYNAMICS BY APPLICATION
9.13 SIGNALS TO WATCH, 2026–2030
9.14 STRATEGIC IMPLICATIONS BY STAKEHOLDER
9.15 BOTTOM LINE

SECTION 10 - MARKET ANALYSIS BY END-USE ORGANIZATION / BUYER TYPE

10.1 EXECUTIVE TAKEAWAYS
10.2 GLOBAL FORECAST BY END-USE ORGANIZATION
10.3 END-USE ORGANIZATION DEFINITIONS
10.4 HOSPITALS / IDNS
10.5 IMAGING CENTERS / RADIOLOGY GROUPS
10.6 TELERADIOLOGY PROVIDERS
10.7 CLINICS / SPECIALIST OFFICES
10.8 OTHER / GOVERNMENT, MOBILE, MILITARY, NGO
10.9 END-USE ORGANIZATION X REVENUE MODEL CROSSWALK
10.10 END-USE ORGANIZATION X CLINICAL APPLICATION CROSSWALK
10.11 REGIONAL READOUT BY BUYER TYPE
10.12 COMPETITIVE DYNAMICS BY BUYER TYPE
10.13 SIGNALS TO WATCH, 2026–2030
10.14 STRATEGIC IMPLICATIONS BY STAKEHOLDER
10.15 BOTTOM LINE

SECTION 11 - MARKET ANALYSIS BY AI TECHNOLOGY / MODEL ARCHITECTURE

11.1 EXECUTIVE TAKEAWAYS
11.2 GLOBAL FORECAST BY AI TECHNOLOGY
11.3 TECHNOLOGY DEFINITIONS
11.4 DEEP LEARNING / CNNS / TRANSFORMER-ENHANCED IMAGING MODELS
11.5 CLASSICAL COMPUTER VISION
11.6 TRADITIONAL MACHINE LEARNING / RADIOMICS
11.7 NLP / GENAI / REPORTING AI
11.8 ROBOTICS / AUTOMATION / IMAGE-GUIDED AI
11.9 EXPERT SYSTEMS / RULE ENGINES
11.10 FOUNDATION MODELS / MULTIMODAL AI OVERLAY
11.11 TECHNOLOGY X APPLICATION CROSSWALK
11.12 REGIONAL TECHNOLOGY READOUT
11.13 COMPETITIVE DYNAMICS BY TECHNOLOGY LAYER
11.14 SIGNALS TO WATCH, 2026–2030
11.15 STRATEGIC IMPLICATIONS BY STAKEHOLDER
11.16 BOTTOM LINE

SECTION 12 - MARKET ANALYSIS BY REIMBURSEMENT TIER / PAYMENT MATURITY

12.1 EXECUTIVE TAKEAWAYS
12.2 GLOBAL FORECAST BY REIMBURSEMENT TIER
12.3 REIMBURSEMENT TIER DEFINITIONS
12.4 TIER 1 - MATURE REIMBURSEMENT
12.5 TIER 2 - DEVELOPING REIMBURSEMENT
12.6 TIER 3 - NO AI-SPECIFIC REIMBURSEMENT
12.7 HARDWARE-EMBEDDED / OUT-OF-TIER AI
12.8 REGIONAL REIMBURSEMENT READOUT
12.9 REIMBURSEMENT TIER X APPLICATION CROSSWALK
12.10 VENDOR IMPLICATIONS BY REIMBURSEMENT TIER
12.11 REIMBURSEMENT SIGNALS TO WATCH, 2026–2030
12.12 SCENARIO IMPLICATIONS
12.13 STRATEGIC IMPLICATIONS BY STAKEHOLDER
12.14 BOTTOM LINE

SECTION 13 - COMPETITIVE ARCHITECTURE & STRATEGIC POSITIONING

13.1 COMPETITIVE ARCHITECTURE THESIS: THE MARKET IS MOVING FROM ALGORITHM OWNERSHIP TO WORKFLOW CONTROL
13.2 COMPETITIVE ARCHITECTURE: SEVEN POWER CENTERS ARE EMERGING
13.3 HOW COMPETITION WORKS: THE MOAT HAS MOVED UP THE STACK
13.4 OEM PLATFORM INCUMBENTS: SCANNER CONTROL IS STILL POWERFUL, BUT NOT SUFFICIENT
13.5 AI-NATIVE PLATFORMS AND FOUNDATION MODELS: THE PLATFORM THESIS HAS REAL MOMENTUM
13.6 REPORTING, DOCUMENTATION, AND GENAI: THE REPORT IS BECOMING THE NEXT CONTROL PLANE
13.7 POINT-SOLUTION AI: CLEARANCE IS NO LONGER ENOUGH
13.8 REIMBURSED SPECIALIST LAYER: CLINICAL UTILITY BEATS BREADTH
13.9 ENTERPRISE IMAGING PLATFORMS: THE VIEWER IS BECOMING THE AI DISTRIBUTION CHANNEL
13.10 NEUTRAL MARKETPLACES AND AI AGGREGATORS: USEFUL LAYER, FRAGILE ECONOMICS
13.11 HYPERSCALERS AND INFRASTRUCTURE: ENABLERS, NOT YET PRIMARY CLINICAL WINNERS
13.12 PROVIDER-PLATFORM HYBRIDS: BUYERS ARE BECOMING VENDORS
13.13 REGIONAL VENDOR ECOSYSTEMS
13.14 COMPETITIVE WINNERS, WATCHLIST, AND AT-RISK SEGMENTS
13.15 M&A AND PARTNERSHIP IMPLICATIONS
13.16 STRATEGIC IMPLICATIONS BY AUDIENCE
13.17 SECTION 13 BOTTOM LINE

SECTION 14 - COMMERCIALIZATION, PRICING & REIMBURSEMENT ARCHITECTURE

14.1 COMMERCIALIZATION THESIS: AI IMAGING IS MOVING FROM FEATURE MONETIZATION TO ECONOMIC CAPTURE
14.2 THE REIMBURSEMENT TIER FRAMEWORK: THE MOST IMPORTANT COMMERCIAL SEGMENTATION
14.3 CARDIAC CT AI IS THE COMMERCIAL BENCHMARK
14.4 PRICING MODELS: FIVE COMMERCIAL ARCHETYPES ARE EMERGING
14.5 PACKAGING LADDER: AI MUST MOVE FROM MODULES TO OPERATING-LAYER ECONOMICS
14.6 BUYER-SPECIFIC MONETIZATION: THE SAME AI PRODUCT NEEDS DIFFERENT COMMERCIAL MOTIONS
14.7 REIMBURSEMENT PATHWAYS: DETECTION ALONE RARELY WINS
14.8 DIRECT-TO-CONSUMER AND PATIENT-PAID AI: USEFUL BUT NOT UNIVERSAL
14.9 CLOUD / PAY-PER-USE: THE LONG-TERM MARGIN POOL
14.10 OEM COMMERCIAL STRATEGY: EMBED HYGIENE AI, MONETIZE OUTCOMES AI
14.11 PLATFORM VENDOR STRATEGY: WIN THE INTEGRATION BUDGET, NOT JUST THE ALGORITHM BUDGET
14.12 REGIONAL MONETIZATION MODELS: ONE GLOBAL PRICING STRATEGY FAILS
14.13 COMMERCIALIZATION BY USE CASE: WHAT GETS PAID, WHAT GETS BUNDLED, WHAT GETS BURIED
14.14 CONTRACTING GUARDRAILS: WHAT VENDORS SHOULD NOT DO
14.15 COMMERCIAL KPIS: THE METRICS THAT DETERMINE RENEWAL
14.16 SECTION TAKEAWAYS

SECTION 15 - REGULATORY, EVIDENCE & GOVERNANCE ROADMAP

15.1 SECTION THESIS: CLEARANCE IS NO LONGER THE FINISH LINE
15.2 GLOBAL REGULATORY ARCHITECTURE: FOUR DISTINCT MARKETS, NOT ONE
15.3 U.S. REGULATORY AND COVERAGE PATHWAY: FDA CLEARANCE IS NECESSARY BUT NOT SUFFICIENT
15.4 FDA AND CHANGE CONTROL: PCCP BECOMES A STRATEGIC ADVANTAGE
15.5 EUROPE: MDR + AI ACT TURNS COMPLIANCE INTO A COMPETITIVE MOAT
15.6 EU SIMPLIFICATION COULD HELP, BUT NOT ENOUGH TO REMOVE THE COMPLIANCE TAX
15.7 CHINA: INDUSTRIAL POLICY, PROCUREMENT, AND DATA LOCALIZATION DEFINE THE MARKET
15.8 JAPAN: THE MOST ATTRACTIVE APPROVAL-TO-PAYMENT COUPLING OUTSIDE THE U.S.
15.9 EVIDENCE HIERARCHY: THE BAR IS MOVING FROM AUC TO OUTCOMES
15.10 MAMMOGRAPHY AI IS THE EVIDENCE BENCHMARK
15.11 CT AI AND FOUNDATION MODELS: EVIDENCE IS LAGGING COMMERCIAL EXCITEMENT
15.12 POST-MARKET SURVEILLANCE: THE NEXT GOVERNANCE BATTLEGROUND
15.13 CYBERSECURITY AND PLATFORM RELIABILITY ARE NOW COMMERCIAL ISSUES
15.14 LIABILITY AND HUMAN OVERSIGHT: AUTONOMOUS AI REMAINS CONSTRAINED
15.15 REGULATORY FRICTION FAVORS INCUMBENTS BUT DOES NOT GUARANTEE PLATFORM SUCCESS
15.16 REGULATORY AND EVIDENCE SCORECARD BY USE CASE
15.17 ENTERPRISE AI GOVERNANCE BLUEPRINT
15.18 REGULATORY WATCHLIST: 2026–2030
15.19 STRATEGIC RECOMMENDATIONS
15.20 SECTION TAKEAWAYS

SECTION 16 - SCENARIO OUTLOOK, FORECAST SENSITIVITY & STRATEGIC PRIORITIES

16.1 SECTION THESIS: THE MARKET IS STILL HIGH-GROWTH, BUT THE EASY GROWTH ASSUMPTION IS GONE
16.2 UPDATED FORECAST ARCHITECTURE: TAM, SAM, AND EXPECTED MARKET
16.3 WHY THE GROWTH CURVE WAS REVISED
16.4 BASE, BULL, BEAR, AND TAIL RISK SCENARIOS
16.5 BASE CASE: WHAT MUST GO RIGHT
16.6 BULL CASE: WHAT CREATES THE UPSIDE
16.7 BEAR CASE: WHAT BREAKS THE FORECAST
16.8 SENSITIVITY RANKING: THE FIVE VARIABLES THAT MATTER MOST
16.9 REIMBURSEMENT TIER MIGRATION: THE CORE ECONOMIC RESET
16.10 REGIONAL FORECAST: ONE GLOBAL MARKET, FOUR COMMERCIAL CLOCKS
16.11 COUNTRY IMPLICATIONS: THE U.S. STILL LEADS MONETIZATION, BUT INDIA AND CHINA GAIN STRATEGIC WEIGHT264
16.12 MODALITY READOUT: CT ANCHORS REIMBURSEMENT; MRI BECOMES THE LARGEST 2035 POOL
16.13 FOUNDATION MODELS: THE LARGEST UPSIDE AND LARGEST DOWNSIDE DRIVER
16.14 PLATFORM CONTROL VS ALGORITHM DIFFERENTIATION
16.15 OEM ECONOMICS: SERVICE AND RECURRING REVENUE REMAIN THE MOAT
16.16 INVESTMENT IMPLICATIONS
16.17 FORECAST CHECKPOINT CALENDAR
16.18 STRATEGIC PRIORITIES BY STAKEHOLDER
16.19 SECTION TAKEAWAYS

SECTION 17 - STRATEGIC EXECUTION PLAYBOOK, COMMERCIALIZATION ROADMAP & BOARD-LEVEL ACTIONS

17.1 SECTION THESIS: THE MARKET HAS MOVED FROM FORECASTING TO EXECUTION
17.2 STRATEGIC PRIORITY STACK: WHAT MANAGEMENT TEAMS SHOULD DO FIRST
17.3 THE FOUR STRATEGIC RULES FOR AI IMAGING VENDORS
17.4 COMMERCIAL PLAYBOOK BY VENDOR ARCHETYPE
17.5 REIMBURSEMENT-LED GTM FRAMEWORK
17.6 PRODUCT ARCHITECTURE: BUILD FOR THE ENTERPRISE, NOT THE DEMO
17.7 PRICING AND CONTRACTING ARCHITECTURE
17.8 EVIDENCE STRATEGY: BUILD THE REIMBURSEMENT FILE BEFORE THE PAYER MEETING
17.9 REGIONAL EXECUTION PLAYBOOK
17.10 M&A AND PARTNERSHIP PLAYBOOK
17.11 PROVIDER IMPLEMENTATION BLUEPRINT
17.12 INVESTOR DILIGENCE SCORECARD
17.13 BOARD-LEVEL KPI DASHBOARD
17.14 2026–2030 WATCHLIST
17.15 NO-REGRET MOVES BY STAKEHOLDER
17.16 STRATEGIC SYNTHESIS: WHAT “WINNING” LOOKS LIKE BY
17.17 SECTION TAKEAWAYS

SECTION 18 - APPENDIX, WATCHLIST & KPI DASHBOARD

18.1 SECTION THESIS: THE MARKET NOW REQUIRES CONTINUOUS SIGNAL MONITORING
18.2 2026–2030 EXECUTIVE WATCHLIST
18.3 TOP 25 SIGNALS TO TRACK THROUGH
18.4 2026–2030 SIGNAL CALENDAR
18.5 BOARD-LEVEL KPI DASHBOARD
18.6 FORECAST REVISION TRIGGER RULES
18.7 METHODOLOGY NOTES
18.8 SEGMENTATION DEFINITIONS
18.9 METHODOLOGICAL GUARDRAILS FOR FORECAST INTERPRETATION
18.10 FORECAST RISK REGISTER
18.11 GREEN-FLAG / RED-FLAG SCORECARD
18.12 GLOSSARY
18.13 APPENDIX: CRITICAL ASSUMPTIONS REGISTER